NASDAQ:BBIO

BridgeBio Pharma (BBIO) Stock Forecast, Price & News

$26.37

-0.76 (-2.80%)

(As of 09/29/2023 ET)

Compare

Today's Range: $26.07
▼
$27.39
50-Day Range: $26.34
▼
$35.01
52-Week Range: $6.64
▼
$36.36

Volume: 1.54 million shs
Average Volume: 1.70 million shs
Market Capitalization: $4.28 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $37.30

BridgeBio Pharma MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.90 Rating Score
Upside/Downside: 41.4% Upside
$37.30 Price Target
Short Interest: Bearish
13.61% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.31
Upright™ Environmental Score
News Sentiment: 0.46
Based on 8 Articles This Week
Insider Trading: Selling Shares
$54.62 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.51) to ($2.87) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

144th out of 972 stocks

Pharmaceutical Preparations Industry

48th out of 449 stocks

4.5

Analyst's Opinion

Consensus Rating
BridgeBio Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.30, BridgeBio Pharma has a forecasted upside of 41.4% from its current price of $26.37.
Amount of Analyst Coverage
BridgeBio Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
13.61% of the float of BridgeBio Pharma has been sold short.
Short Interest Ratio / Days to Cover
BridgeBio Pharma has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in BridgeBio Pharma has recently increased by 4.24%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
BridgeBio Pharma does not currently pay a dividend.
Dividend Growth
BridgeBio Pharma does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
BridgeBio Pharma has received a 53.04% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Infigratinib", "Fosdenopterin", and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for BridgeBio Pharma is -2.31.

1.9

News and Social Media Coverage

News Sentiment
BridgeBio Pharma has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for BridgeBio Pharma this week, compared to 4 articles on an average week.
Search Interest
Only 6 people have searched for BBIO on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $54,622,379.00 in company stock.
Percentage Held by Insiders
28.52% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
90.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BridgeBio Pharma are expected to grow in the coming year, from ($3.51) to ($2.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BridgeBio Pharma is -7.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BridgeBio Pharma is -7.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BBIO Price History

30 days | 90 days | 365 days | Advanced Chart

BBIO Stock News Headlines

September 29, 2023 | americanbankingnews.com

Leerink Partnrs Weighs in on BridgeBio Pharma, Inc.'s Q3 2023 Earnings (NASDAQ:BBIO)

September 25, 2023 | seekingalpha.com

BridgeBio Pharma to issue 9.2M shares through PIPE financing

October 1, 2023 | Vector Vest (Ad)

Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

September 25, 2023 | markets.businessinsider.com

BridgeBio Pharma Announces $250 Mln PIPE Financing

September 25, 2023 | msn.com

Qatar Investment Authority Leads $250M PIPE Financing in BridgeBio (NASDAQ:BBIO)

September 14, 2023 | markets.businessinsider.com

BridgeBio Pharma (BBIO) Gets a Buy from Goldman Sachs

September 7, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BridgeBio Pharma (BBIO) and BioMarin Pharmaceutical (BMRN)

September 7, 2023 | finance.yahoo.com

BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

October 1, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

September 6, 2023 | finance.yahoo.com

BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

August 30, 2023 | seekingalpha.com

BridgeBio: Positive Updated Acoramidis Data May Not Imply Further Upside

August 30, 2023 | msn.com

What's Going On With BridgeBio Pharma Stock Today?

August 28, 2023 | msn.com

Mizuho Reiterates BridgeBio Pharma (BBIO) Buy Recommendation

August 28, 2023 | msn.com

Pfizer Was First In Treating This Heart Disease. Why BridgeBio Could Be Better.

August 27, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Paycor HCM (PYCR), BridgeBio Pharma (BBIO) and Evolent Health (EVH)

August 27, 2023 | finance.yahoo.com

BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023

August 24, 2023 | finance.yahoo.com

BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023

August 24, 2023 | benzinga.com

BridgeBio Pharma Unusual Options Activity

August 21, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Neurocrine (NBIX), Teva Pharmaceutical (TEVA)

August 18, 2023 | msn.com

JP Morgan Maintains BridgeBio Pharma (BBIO) Overweight Recommendation

August 9, 2023 | finance.yahoo.com

Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It?

August 3, 2023 | finanznachrichten.de

BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update

August 3, 2023 | finance.yahoo.com

BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates

August 3, 2023 | finance.yahoo.com

BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update

August 2, 2023 | msn.com

BridgeBio Pharma (BBIO) Price Target Increased by 59.14% to 46.35

July 31, 2023 | finance.yahoo.com

BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study

July 28, 2023 | fool.com

BridgeBio Pharma (NASDAQ: BBIO)

See More Headlines

Receive BBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter.

BBIO Company Calendar

Last Earnings: 8/03/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BBIO
CUSIP: N/A
CIK: 1743881
Web: bridgebio.com
Phone: (650) 391-9740
Fax: N/A
Employees: 392
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $37.30
High Stock Price Forecast: $60.00
Low Stock Price Forecast: $18.00
Forecasted Upside/Downside: +41.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.90
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.75)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-481,180,000.00
Net Margins: -10,096.65%
Pretax Margin: -10,294.24%
Return on Equity: N/A
Return on Assets: -91.14%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.93
Quick Ratio: 3.93

Sales & Book Value

Annual Sales: $77.65 million
Price / Sales: 55.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($8.32) per share
Price / Book: -3.17

Miscellaneous

Outstanding Shares: 162,470,000
Free Float: 116,135,000
Market Cap: $4.28 billion
Optionable: Not Optionable
Beta: 0.97

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Neil Kumar Ph.D. (Age 44)
Co-Founder, Pres, CEO & Director
Comp: $2.1M

Dr. Charles J. Homcy M.D. (Age 75)
Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
Comp: $208k

Dr. Brian C. Stephenson C.F.A. (Age 42)
Ph.D., CFO & Sec.
Comp: $1.15M

Dr. Richard H. Scheller Ph.D. (Age 70)
Chairman of R&D
Comp: $202.4k

Dr. Frank P. McCormick Ph.D. (Age 73)
Co-Founder & Chairman of Oncology

Dr. Uma Sinha Ph.D. (Age 66)
Chief Scientific Officer

Grace Rauh
VP of Communications

Mr. Eli M. Wallace Ph.D. (Age 56)
Chief Scientific Officer of Oncology

Dr. Thomas Trimarchi Ph.D.
Chief Product Officer

Dr. Eric Michael David J.D. (Age 51)
M.D., Ph.D., Chief Exec. Officer of Gene Therapy

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BBIO Stock - Frequently Asked Questions

Should I buy or sell BridgeBio Pharma stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BBIO shares.
View BBIO analyst ratings or view top-rated stocks.
What is BridgeBio Pharma's stock price forecast for 2023?: 10 Wall Street research analysts have issued 12-month price targets for BridgeBio Pharma's stock. Their BBIO share price forecasts range from $18.00 to $60.00. On average, they expect the company's share price to reach $37.30 in the next twelve months. This suggests a possible upside of 41.4% from the stock's current price.
View analysts price targets for BBIO or view top-rated stocks among Wall Street analysts.
How have BBIO shares performed in 2023?: BridgeBio Pharma's stock was trading at $7.62 on January 1st, 2023. Since then, BBIO shares have increased by 246.1% and is now trading at $26.37.
View the best growth stocks for 2023 here.
When is BridgeBio Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our BBIO earnings forecast.
How were BridgeBio Pharma's earnings last quarter?: BridgeBio Pharma, Inc. (NASDAQ:BBIO) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.18. The firm earned $1.60 million during the quarter, compared to analyst estimates of $2.99 million. The company's revenue for the quarter was down 97.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.07) EPS.
What ETFs hold BridgeBio Pharma's stock?: ETFs with the largest weight of BridgeBio Pharma (NASDAQ:BBIO) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), First Trust Small Cap Growth AlphaDEX Fund (FYC), Invesco Nasdaq Biotechnology ETF (IBBQ) and Pacer WealthShield ETF (PWS).

What other stocks do shareholders of BridgeBio Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU), Editas Medicine (EDIT), Block (SQ), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT).
When did BridgeBio Pharma IPO?: (BBIO) raised $225 million in an IPO on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR acted as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.
What is BridgeBio Pharma's stock symbol?: BridgeBio Pharma trades on the NASDAQ under the ticker symbol "BBIO."
How do I buy shares of BridgeBio Pharma?: Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BridgeBio Pharma's stock price today?: One share of BBIO stock can currently be purchased for approximately $26.37.
How much money does BridgeBio Pharma make?: BridgeBio Pharma (NASDAQ:BBIO) has a market capitalization of $4.28 billion and generates $77.65 million in revenue each year. The company earns $-481,180,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis.
How many employees does BridgeBio Pharma have?: The company employs 392 workers across the globe.
How can I contact BridgeBio Pharma?: BridgeBio Pharma's mailing address is 421 Kipling Street, Palo Alto CA, 94301. The official website for the company is bridgebio.com. The company can be reached via phone at (650) 391-9740.

This page (NASDAQ:BBIO) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial